S44563 is a potent, dual Bcl-2/Bcl-XL inhibitor with IC50 of 131 and 140 nM, respectively.

S3I-M2001 (Bromohydroxyacetone phosphate) is an oxazole-based peptidomimetic of the STAT3 SH2 domain-binding phosphotyrosine peptide that selectively disrupts active STAT3:STAT3 dimers.

S-3448 is a potent, specific soluble guanylate cyclase (sGC) activator with EC50 of 0.68 uM, preferentially activates the NO-insensitive heme-oxidized form of sGC.

S-2101 is a potent lysine-specific demethylase 1 (LSD1) inhibitor with Ki of 0.61 uM.

S1P1 Agonist 8 is a potent, selective, orally bioavailable S1P1 receptor agonist with EC50 of 35 nM (S1P1 internalization), >100-fold selectivity over against receptor subtypes S1P2-5.

S1p receptor agonist 1 is an S1P receptor agonist extracted from patent WO 2015039587 A1, compound example 2.

S130 (ATG4B inhibitor S130) is a potent, specific ATG4B inhibitor with IC50 of 3.24 uM, shows strong affinity (Kd=4 uM) and specifically suppresses the activity of ATG4B, but not other proteases.

Ryanodine is a cell permeant ryanodine receptor modulator. Ryanodine can either stimulate or inhibit Ryanodine-mediated Ca2+ release depending on its concentrations. Poisonous diterpenoid found in Ryania speciosa.

RVX-297 is a novel orally active, BD2 selective, BET bromodomain inhibitor with Alpha Screen IC50 of 0.08, 0.05 and 0.02 uM for BRD2 (BD2), BRD3 (BD2) and BRD4 (BD2), respectively.

RVX2135 is a novel potent and orally bioavailable inhibitor of Brd2, Brd3, Brd4, and BrdT with IC50 of 1.31, 0.58, 0.44, and 1.58 uM, respectively.

RV-1729 is a potent, selective PI3Kδ inhibitor with IC50 of 12 nM, 2-fold selectivity for PI3Kδ relative to PI3Kγ and 16-fold over PI3Kα.

RV1088 is a potent narrow spectrum kinase inhibitor that target p38, c-Src, Syk or JAK individually, dose-dependently reduces TNF-α levels in LPS-activated macrophages with IC50 of 0.63 nM.

Rutin hydrate is a flavonol glycoside, able to cross the blood-brain barrier, and acts by inhibiting JNK and ERK1/2 activation and activating mTOR signalling.

RU-SKI 43 Hcl is a small molecule inhibitor of Hhat(Hedgehog acyltransferase), the enzyme responsible for the attachment of palmitate onto Shh.

Rufloxacin is a fluoroquinolone antibiotic.

RU-A1 is a novel potent BMI1 inhibitor that targets cellular self-renewal in hepatocellular carcinoma (HCC).

RU-505 is an effective inhibitor of the Aβ42-fibrinogen interaction with IC50 of 2.72 uM in FP assays.

RTC-5 is a dual pathway inhibitor of PI3K-AKT and RAS-ERK signaling via putative activation of the tumor suppressor PP2A, exhibits GI50 of 12.6 uM against H1650 lung adenocarcinoma cells.

RTC-30 is an orally active, dual pathway inhibitor of PI3K-AKT and RAS-ERK signaling via putative activation of the tumor suppressor PP2A, exhibits GI50 of 15 uM against H1650 lung adenocarcinoma cells.

RSV-IN-1 is a human respiratory syncytical virus (hRSV) inhibitor, with an IC50 of 0.11 μM.

RSV604 racemate is a racemic mixture, shows less potency against strains of respiratory syncytial virus (RSV) than the S-isomer.

RSV604 R enantiomer is the R-enantiomer of RSV604, which is a potent respiratory syncytial virus (RSV) inhibitor targeting the nucleocapsid protein, is less active against RSV..

RSV inhibitor compound 1 is a novel potent, orally bioavailable RSV fusion inhibitor with EC50 of 2 nM (RSV Long strain infected HEp-2 cells) without significant cytotoxicity (CC50>100 uM).

RSK2-IN-20 is a potent, selective, and durable inhibitpr of RSK2 with IC50 of 47 nM.

RS 17053 hydrochloride is a potent and selective α1A adrenoceptor antagonist, with a pKi value of 9.1 in native cell membrane and a pA2 value of 9.8 in functional assays.

RRD-251 hydrochloride is a small molecule disruptor of Rb/Raf-1 interaction, potently and selectively disrupts the Rb/Raf-1 (IC50=77 nM) but not Rb/E2F, Rb/prohibitin, Rb/cyclin E, and Rb/HDAC binding.

RRD-251 hydrochloride is a small molecule disruptor of Rb/Raf-1 interaction, potently and selectively disrupts the Rb/Raf-1 (IC50=77 nM) but not Rb/E2F, Rb/prohibitin, Rb/cyclin E, and Rb/HDAC binding.

RPR260243 was the first reported hERG channel activator.

Rpn11 inhibitor 35 is a potent, small molecule inhibitor of the proteasome subunit Rpn11 with IC50 of 400 nM,100-fold selectivity over Csn5 and 10-fold selectivity over AMSH.

RPL-554 (LS-193855, RPL554) is a potent, orally available, dual PDE3/PDE4 inhibitor with IC50 of 0.4 nM and 1479 nM, respectively.